)
)
)
Synklino
Company Description: Synklino is a clinical stage biotechnology company pioneering transformative therapies for solid organ transplantation. Our first-in-class breakthrough drug candidate, SYN002, is a therapeutic fusion protein designed to eliminate both active and latent CMV infection in donated organs through ex vivo organ perfusion, offering a proactive and life-changing therapy for immunocompromised transplant recipients. Following recent regulatory approval, SYN002 is set to enter clinical development in kidney transplantation in in the coming months.
Goal for Presentation: To introduce Synklino and provide an overview of our first in class SYN002 therapy, including its scientific rationale and clinical development strategy. To increase awareness of Synklino among potential strategic partners and collaborators, including opportunities for research, development, and commercial partnerships. To engage with parties interested in longer-term strategic options, including potential M&A discussions. To present Synklino as an investment opportunity, highlighting that the company is funded to complete its Phase 1 clinical study through 2026 and is seeking capital to prepare for and execute a Phase 2 clinical program
Additional Comments:
Who referred you to this application?:
Goal for Presentation: To introduce Synklino and provide an overview of our first in class SYN002 therapy, including its scientific rationale and clinical development strategy. To increase awareness of Synklino among potential strategic partners and collaborators, including opportunities for research, development, and commercial partnerships. To engage with parties interested in longer-term strategic options, including potential M&A discussions. To present Synklino as an investment opportunity, highlighting that the company is funded to complete its Phase 1 clinical study through 2026 and is seeking capital to prepare for and execute a Phase 2 clinical program
Additional Comments:
Who referred you to this application?:
What is your next catalyst (value inflection) update?
Clinical phase 1 data, safety, Pk and potential efficacy signal
Year Founded
2017
Lead Product in Development
SYN002, is a therapeutic fusion protein designed to eliminate both active and latent CMV infection in donated organs through ex vivo organ perfusion, offering a proactive and life-changing therapy for immunocompromised transplant recipients
Development Phase of Lead Product
Phase I
Number of Unlicensed Products Looking for Licensing
1 (SYN002)
CEO/Top Company Official
Thomas Kledal
When you expect your next catalyst update?
Spring/summer 2026, initial readout from phase 1 clinical trial
){kind=logo}
)
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
